Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382448 | 0.89 | ALDH1A1 (0.38) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL16848723 | 0.89 | KMT2A (0.42) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL10105974 | 0.88 | L3MBTL1 (0.42) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL2633144 | 0.83 | ALDH1A1 (0.44) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL13221517 | 0.83 | ALDH1A1 (0.42) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL6254346 | 0.80 | ALDH1A1 (0.33) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL21504417 | 0.80 | HPGD (0.40) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL4432965 | 0.80 | GAA (0.36) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL21167217 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL109045 | 0.79 | ALDH1A1 (0.54) | ALDH1A1HPGDMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2038 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144860-A1 | HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2026-05-28 | — | — | US | claimed |
| US-12458691-B2 | HIV-1 ENV fusion peptide immunogens and their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-11-04 | — | — | US | claimed |
| US-20250295745-A1 | CROSS-LINKED TUMOR LYSATE SPHERICAL NUCLEIC ACIDS AS CANCER VACCINES | NORTHWESTERN UNIVERSITY | 2025-09-25 | — | — | US | claimed |
| US-12329822-B2 | Antimicrobial tailored chitosan | UNIVERSITÉ DE GENVE (CH) | 2025-06-17 | — | — | US | claimed |
| CN-112533640-B | Targeting of M2-type tumor-associated macrophages using melittin-based apoptosis-inducing peptides | 双亥生命科学株式会社 | 2025-02-28 | — | — | CN | claimed |
| US-20240293524-A1 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-09-05 | — | — | US | claimed |
| EP-3965887-B1 | ANTIMICROBIAL CHITOSAN | UNIV GENEVE (CH) | 2024-02-28 | — | — | EP | claimed |
| US-20240052005-A1 | IMPROVED CELL-PENETRATING PEPTIDES AND FUSION PROTEINS | ANASTASIS BIOTEC LIMITED (GB) | 2024-02-15 | — | — | US | claimed |
| WO-2023220678-A1 | CROSS-LINKED TUMOR LYSATE SPHERICAL NUCLEIC ACIDS AS CANCER VACCINES | NORTHWESTERN UNIVERSITY (US) | 2023-11-16 | — | — | WO | claimed |
| US-20230338507-A1 | HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-26 | — | — | US | claimed |
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2023-05-04 | — | — | US | claimed |
| CN-115996942-A | Macrophage-targeting peptides, conjugates, compositions and uses thereof | 双亥生命科学株式会社 | 2023-04-21 | — | — | CN | claimed |
| US-11602559-B2 | HIV-1 Env fusion peptide immunogens and their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-03-14 | — | — | US | claimed |
| EP-4070815-A1 | HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2022-10-12 | — | — | EP | claimed |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | EXELIXIS, INC. | 2022-08-18 | — | — | US | claimed |
| US-20220193244-A1 | ANTIMICROBIAL TAILORED CHITOSAN | UNIVERSITE DE GENEVE (CH) | 2022-06-23 | — | — | US | claimed |
| WO-2022129926-A1 | IMPROVED CELL-PENETRATING PEPTIDES AND FUSION PROTEINS | ANASTASIS BIOTEC LIMITED (GB) | 2022-06-23 | — | — | WO | claimed |
| EP-3994150-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | Iconic Therapeutics, Inc. (US) | 2022-05-11 | — | — | EP | claimed |
| CN-114222752-A | Anti-tissue factor antibody-drug conjugates and related methods | 伊科尼克治疗公司 | 2022-03-22 | — | — | CN | claimed |
| EP-1328811-B1 | HCV MOSAIC ANTIGEN COMPOSITION | MEDMIRA INC (CA) | 2005-08-31 | — | — | EP | claimed |